• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在老年人中,脂肪性肝病是多种疾病的一个标志,而非潜在肝硬化的标志。

Steatotic liver disease is a marker of multimorbidity, not underlying cirrhosis, in older adults.

作者信息

Oduwole O, Ding C, Bitar N, Nair D, Salter S, Silverman M, Allen R, Ng Fat L, Tsochatzis E, Bell S, Mehta G, Britton A

机构信息

Institute for Liver and Digestive Health, University College London, London, UK.

Department of Clinical Biochemistry, Royal Free Hospital, London, UK.

出版信息

NPJ Gut Liver. 2025;2(1):10. doi: 10.1038/s44355-025-00024-0. Epub 2025 May 5.

DOI:10.1038/s44355-025-00024-0
PMID:40336824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12052588/
Abstract

Steatotic liver disease (SLD) prevalence in adults is estimated at 30%, but older populations are understudied. Here, SLD prevalence and associated risk factors were assessed 1,021 Whitehall II study participants (mean age 72.5) using transient elastography (FibroScan). SLD was present in 33.3% (CAP ≥ 275 dB/m), with most classified as metabolic dysfunction-associated SLD. Only 2.4% had significant fibrosis ( ≥ 7.9 kPa). Adjusted for age and sex, SLD was associated with low physical activity (OR 1.60, 95% CI 1.13-2.27), poorer motor function (SF-36 PCS OR 1.21, 95% CI 1.05-1.40), difficulties in activities of daily living (OR 3.19, 95% CI 1.17-8.64), and multimorbidity (OR 1.45, 95% CI 1.22-1.73). These associations persisted after adjustment for socioeconomic, behavioural, and cardiometabolic risk factors. Frailty was associated with SLD at higher CAP thresholds ( ≥ 290 dB/m). In this older adult sample, SLD is common and appears more as a marker of multimorbidity and low physical activity than significant fibrosis.

摘要

成人脂肪性肝病(SLD)的患病率估计为30%,但对老年人群的研究不足。在此,我们使用瞬时弹性成像(FibroScan)对1021名白厅II研究参与者(平均年龄72.5岁)的SLD患病率及相关危险因素进行了评估。33.3%的人存在SLD(CAP≥275dB/m),大多数被归类为代谢功能障碍相关的SLD。只有2.4%的人有显著纤维化(≥7.9kPa)。在对年龄和性别进行调整后,SLD与低体力活动(比值比1.60,95%置信区间1.13 - 2.27)、较差的运动功能(SF - 36身体功能评分比值比1.21,95%置信区间1.05 - 1.40)、日常生活活动困难(比值比3.19,95%置信区间1.17 - 8.64)以及多种疾病并存(比值比1.45,95%置信区间1.22 - 1.73)相关。在对社会经济、行为和心脏代谢危险因素进行调整后,这些关联依然存在。在较高的CAP阈值(≥290dB/m)下,衰弱与SLD相关。在这个老年成人样本中,SLD很常见,并且似乎更多地是多种疾病并存和低体力活动的一个标志,而非显著纤维化的标志。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/bd872b129366/44355_2025_24_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/c7525d7aa349/44355_2025_24_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/295eb6dd231a/44355_2025_24_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/bd872b129366/44355_2025_24_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/c7525d7aa349/44355_2025_24_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/295eb6dd231a/44355_2025_24_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/432c/12052588/bd872b129366/44355_2025_24_Fig3_HTML.jpg

相似文献

1
Steatotic liver disease is a marker of multimorbidity, not underlying cirrhosis, in older adults.在老年人中,脂肪性肝病是多种疾病的一个标志,而非潜在肝硬化的标志。
NPJ Gut Liver. 2025;2(1):10. doi: 10.1038/s44355-025-00024-0. Epub 2025 May 5.
2
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.低至中度饮酒与代谢功能障碍相关脂肪性肝病患者的纤维化增加有关。
J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4.
3
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B.并存的脂肪性肝病与慢性乙型肝炎患者的长期肝脏相关事件无关。
Gastroenterol Rep (Oxf). 2025 Feb 12;13:goaf013. doi: 10.1093/gastro/goaf013. eCollection 2025.
4
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.美国非酒精性脂肪性肝病患者中不同种族和民族差异及不利健康社会决定因素的作用及其在各亚型中的表现。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000324.
5
Impact of steatotic liver disease and non-alcoholic steatohepatitis on cognitive impairment in people living with HIV: A cross-sectional study.脂肪性肝病和非酒精性脂肪性肝炎对 HIV 感染者认知障碍的影响:一项横断面研究。
HIV Med. 2023 Dec;24(12):1233-1243. doi: 10.1111/hiv.13579. Epub 2023 Nov 17.
6
Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.美国青少年的纤维化和脂肪性肝病按新命名法分类。
J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):229-237. doi: 10.1002/jpn3.12230. Epub 2024 May 1.
7
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.2017 - 2023年美国成年人脂肪性肝病和肝纤维化的当前负担
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.
8
Exploring the landscape of steatotic liver disease in the general US population.探索美国普通人群中的脂肪性肝病情况。
Liver Int. 2023 Nov;43(11):2425-2433. doi: 10.1111/liv.15695. Epub 2023 Aug 17.
9
Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.利用2017年美国国家健康与营养检查调查、2020年3月至2021年8月以及2021年8月至2023年8月的数据,通过肝脏弹性成像定义的代谢功能障碍相关脂肪性肝病和纤维化的患病率。
Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001211.
10
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.采用共识命名法的脂肪肝疾病及其分类的全国流行率估计。
Hepatology. 2024 Mar 1;79(3):666-673. doi: 10.1097/HEP.0000000000000604. Epub 2023 Sep 20.

引用本文的文献

1
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.老年人脂肪性肝病:临床意义与未满足的需求
Nutrients. 2025 Jun 30;17(13):2189. doi: 10.3390/nu17132189.

本文引用的文献

1
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?肌肉质量与胰高血糖素样肽-1 受体激动剂:体重减轻的适应性还是失代偿性反应?
Circulation. 2024 Oct 15;150(16):1288-1298. doi: 10.1161/CIRCULATIONAHA.124.067676. Epub 2024 Oct 14.
2
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.有过量饮酒史患者脂肪性肝病新命名法的验证:一项前瞻性队列研究数据分析
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):218-228. doi: 10.1016/S2468-1253(23)00443-0. Epub 2024 Jan 11.
3
Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
老年人代谢功能障碍相关脂肪性肝病与虚弱和社会劣势有关。
Liver Int. 2024 Jan;44(1):39-51. doi: 10.1111/liv.15725. Epub 2023 Sep 12.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新脂肪性肝病命名。
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
5
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
6
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
7
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.一项关于 2 型糖尿病患者非酒精性脂肪性肝病、肝纤维化、肝硬化和肝细胞癌患病率的前瞻性研究。
J Hepatol. 2023 Mar;78(3):471-478. doi: 10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19.
8
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.超重和肥胖人群中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球患病率:一项系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
9
Geographical similarity and differences in the burden and genetic predisposition of NAFLD.非酒精性脂肪性肝病负担及遗传易感性的地理相似性与差异
Hepatology. 2023 Apr 1;77(4):1404-1427. doi: 10.1002/hep.32774. Epub 2022 Oct 11.
10
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.欧洲肝脏研究学会-《柳叶刀》肝脏委员会:保护下一代欧洲人免受肝脏疾病并发症和过早死亡的影响。
Lancet. 2022 Jan 1;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 2.